TENX Strangle Strategy

TENX (Tenax Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.

TENX (Tenax Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $231.1M, a beta of 0.96 versus the broader market, a 52-week range of 5.66-18.38, average daily share volume of 789K, a public-listing history dating back to 1994, approximately 4 full-time employees. These structural characteristics shape how TENX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.96 places TENX roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a strangle on TENX?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current TENX snapshot

As of June 29, 2026, spot at $13.61, ATM IV 59.80%, IV rank 12.38%, expected move 17.14%. The strangle on TENX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.

Why this strangle structure on TENX specifically: TENX IV at 59.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a TENX strangle, with a market-implied 1-standard-deviation move of approximately 17.14% (roughly $2.33 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated TENX expiries trade a higher absolute premium for lower per-day decay. Position sizing on TENX should anchor to the underlying notional of $13.61 per share and to the trader's directional view on TENX stock.

TENX strangle setup

The TENX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With TENX near $13.61, the first option leg uses a $14.29 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed TENX chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 TENX shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$14.29N/A
Buy 1Put$12.93N/A

TENX strangle risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

TENX strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on TENX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on TENX

Strangles on TENX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the TENX chain.

TENX thesis for this strangle

The market-implied 1-standard-deviation range for TENX extends from approximately $11.28 on the downside to $15.94 on the upside. A TENX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current TENX IV rank near 12.38% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on TENX at 59.80%. As a Healthcare name, TENX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to TENX-specific events.

TENX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. TENX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move TENX alongside the broader basket even when TENX-specific fundamentals are unchanged. Always rebuild the position from current TENX chain quotes before placing a trade.

Frequently asked questions

What is a strangle on TENX?
A strangle on TENX is the strangle strategy applied to TENX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With TENX stock trading near $13.61, the strikes shown on this page are snapped to the nearest listed TENX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are TENX strangle max profit and max loss calculated?
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the TENX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 59.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a TENX strangle?
The breakeven for the TENX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current TENX market-implied 1-standard-deviation expected move is approximately 17.14%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on TENX?
Strangles on TENX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the TENX chain.
How does current TENX implied volatility affect this strangle?
TENX ATM IV is at 59.80% with IV rank near 12.38%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related TENX analysis